Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–92.

Article  CAS  PubMed  Google Scholar 

Hypertension [Internet]. World Heart Federation. https://world-heart-federation.org/what-we-do/hypertension/ [cited 2023 Jan 7].

Tocci G, Battistoni A, Passerini J, Musumeci MB, Francia P, Ferrucci A, Volpe M. Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther. 2015;20:121–30.

Article  CAS  PubMed  Google Scholar 

Vukadinović D, Scholz SS, Messerli FH, Weber MA, Williams B, Böhm M, Mahfoud F. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. J Hypertens. 2019;37:2093–103.

Article  PubMed  Google Scholar 

Chen BL, Zhang YZ, Luo JQ, Zhang W. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. 2015;11:309–18.

PubMed  PubMed Central  Google Scholar 

Wellington K, Scott LJ. Azelnidipine. Drugs. 2003;63:2613–21.

Article  CAS  PubMed  Google Scholar 

CDSCO. Recommendations of the SEC [Internet]; 2020. https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/73rdSECCardiovascular%20&%20Renal6fe20.pdf [cited 2022 Dec 24].

Shokoji T, Fujisawa Y, Kiyomoto H, Rahman M, Sun GP, Fan YY, Kimura S, Kohno M, Abe Y, Nishiyama A. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res. 2005;28:1017–23.

Article  CAS  PubMed  Google Scholar 

Nakamoto M, Ohya Y, Sakima A, Yamazato M, Takishita S. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats. Hypertens Res. 2007;30:359–66.

Article  CAS  PubMed  Google Scholar 

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007;333:321–6.

Article  PubMed  Google Scholar 

Takenaka T, Seto T, Okayama M, Kojima E, Nodaira Y, Sueyoshi K, Kikuta T, Watanabe Y, Inoue T, Takane H, Ohno Y, Suzuki H. Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study. Am J Nephrol. 2012;35:416–23.

Article  CAS  PubMed  Google Scholar 

Zhao X, Wu F, Jia S, Qu P, Li H, Zhao X, Cao B, Lin Y, Wang M. Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients. Clin Exp Hypertens. 2010;32:372–6.

Article  CAS  PubMed  Google Scholar 

Yamagishi T. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res. 2006;29:767–73.

Article  CAS  PubMed  Google Scholar 

Tawaramoto K, Kaneto H, Hashiramoto M, Kawasaki F, Tatsumi F, Shimoda M, Kamei S, Matsuki M, Mune T, Kaku K. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr. 2015;7:80.

Article  PubMed  PubMed Central  Google Scholar 

Motoki H, Koyama J, Izawa A, Tomita T, Miyashita Y, Takahashi M, Ikeda U. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography. 2014;31:1230–8.

Article  PubMed  Google Scholar 

Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26:201–8.

Article  CAS  PubMed  Google Scholar 

Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, Kawamura M, Tamura H, Okazaki S, Inoue K, Fujiwara Y, Sumiyoshi M, Tanimoto K, Nakazato Y, Yamagami S, Hiro T, Komiyama N, Daida H. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J. 2011;75:1071–9.

Article  CAS  PubMed  Google Scholar 

Inomata J, Murai H, Kaneko S, Hamaoka T, Ikeda T, Kobayashi D, Usui S, Furusho H, Sugiyama Y, Takata S, Takamura M. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. J Hypertens. 2014;32:1898–904.

Article  CAS  PubMed  Google Scholar 

Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, Ohsaka H, Matsumori R, Kurata T, Miyazaki T, Daida H. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function—a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:1–12.

Article  Google Scholar 

Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Fukuda T, Numao T, Shimada K, Kario K. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. J Cardiovasc Pharmacol. 2007;49:394–400.

Article  CAS  PubMed  Google Scholar 

An updated guideline for reporting systematic reviews [Internet]. Equator Network; 2020. https://www.equator-network.org [cited 2022 Dec 24].

PROSPERO [Internet]. University of York. https://www.crd.york.ac.uk/prospero/ [cited 2023 Jan 17].

Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training [Internet]. https://training.cochrane.org/handbook [cited 2022 Dec 24].

RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias [Internet]. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials [cited 2022 Dec 24].

Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training [Internet]. https://training.cochrane.org/handbook#how-to-cite [cited 2023 Aug 20].

Xiao Y, Hu G. The effects of azelnidipine and amlodipine in treatment of mild to moderate hypertension: a systematic review. Int J Clin Exp Med. 2017;10:11273–81.

Google Scholar 

Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, Senda S. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res. 2004;32:170–5.

Article  CAS  PubMed  Google Scholar 

Sofy AA, Abdelsattar AT, Mohammed OM, Shareef MA, Alamodi AA, Nso N, Payton M, Masoud AT. Amlodipine compared with benidipine in the management of hypertension: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2020;27(6):527–37.

Article  CAS  PubMed  Google Scholar 

Ram CVS. Therapeutic usefulness of a novel calcium channel blocker azelnidipine in the treatment of hypertension: a narrative review. Cardiol Ther. 2022;11:473–89.

Article  PubMed  PubMed Central  Google Scholar